Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Has Average Price Target of $128.54

Key Points

• Analysts remain broadly bullish: Sixteen firms give Dianthus Therapeutics an average “Buy” rating, with a consensus 12-month price target of $128.54 versus the stock’s reported $82.38 price. Recent targets range from $113 to $156.
• Institutional ownership increased: Major investors including BlackRock, Wellington Management, ABS Investment Management and Assenagon added or initiated positions, while institutions collectively own 47.53% of the company.
• The company remains unprofitable and insiders have sold shares: Dianthus missed quarterly EPS estimates, reporting a loss of $0.90 per share, while insiders sold 242,429 shares worth approximately $26.1 million over the past three months. The biotech is developing DNTH103, an investigational antibody for autoimmune and inflammatory diseases.

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have received an average rating of "Buy" from the sixteen research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $128.54.

A number of brokerages recently weighed in on DNTH. Wedbush lifted their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an "outperform" rating in a research note on Wednesday, August 5th. Citigroup began coverage on shares of Dianthus Therapeutics in a research report on Friday, September 4th. They issued a "buy" rating and a $156.00 target price for the company. Truist Financial increased their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, September 11th. They issued an "overweight" rating and a $135.00 price objective on the stock. Finally, Roth Capital started coverage on Dianthus Therapeutics in a report on Tuesday, October 27th. They set a "buy" rating and a $113.00 price target for the company.

Insider Activity

In related news, Director Simon Read sold 2,778 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total value of $326,553.90. Following the sale, the director owned 2,778 shares of the company's stock, valued at $326,553.90. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Adam M. Veness sold 16,167 shares of Dianthus Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $110.38, for a total transaction of $1,784,513.46. Following the completion of the sale, the senior vice president directly owned 3,833 shares of the company's stock, valued at approximately $423,086.54. The trade was a 80.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 242,429 shares of company stock valued at $26,118,913. 3.02% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Dianthus Therapeutics during the second quarter valued at about $401,990,000. Wellington Management Group LLP increased its stake in shares of Dianthus Therapeutics by 24.4% in the second quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company's stock worth $314,849,000 after purchasing an additional 634,099 shares in the last quarter. ABS Investment Management LLC purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at $194,960,000. Assenagon Asset Management S.A. boosted its position in Dianthus Therapeutics by 160.9% during the third quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company's stock valued at $64,474,000 after purchasing an additional 451,597 shares in the last quarter. Finally, Jennison Associates LLC acquired a new position in Dianthus Therapeutics during the first quarter valued at $40,713,000. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock opened at $82.38 on Monday. The firm has a market capitalization of $4.51 billion, a PE ratio of -19.85 and a beta of 1.47. The firm has a 50-day moving average price of $92.76 and a 200-day moving average price of $84.60. Dianthus Therapeutics has a 12-month low of $32.28 and a 12-month high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. The business had revenue of $0.76 million during the quarter, compared to analysts' expectations of $0.30 million. As a group, sell-side analysts predict that Dianthus Therapeutics will post -3.81 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company's research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus' lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.